Related Experiment Video

Updated: Mar 27, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.1K

Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists

Ashish Sarraju1, Sun H Kim2, Joshua W Knowles3

  • 1Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Current Atherosclerosis Reports
|January 20, 2016
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) agonists show promise in improving cardiovascular health for individuals with type 2 diabetes. These therapies target cardiometabolic variables and cardiac function, offering a new avenue beyond glucose control.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is the leading cause of death in the USA.
  • Both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) significantly increase CVD risk.
  • Current diabetes management often requires addressing multiple risk factors beyond glycemic control.

Purpose of the Study:

  • To review the cardiovascular effects of glucagon-like peptide-1 (GLP-1) agonists.
  • To focus on the impact of GLP-1 agonists on cardiometabolic variables and cardiac function.
  • To assess the role of GLP-1 agonists in mitigating cardiovascular risk in diabetes.

Main Methods:

  • Literature review of studies on GLP-1 agonists and cardiovascular outcomes.
  • Analysis of clinical trial data and observational studies.
  • Examination of effects on key cardiometabolic markers and cardiac function parameters.

Main Results:

  • GLP-1 agonists demonstrate beneficial effects on cardiovascular health.
  • These agents favorably impact cardiometabolic variables such as blood pressure and lipid profiles.
  • Evidence suggests improvements in cardiac function and potential reduction in cardiovascular events.

Conclusions:

  • GLP-1 agonists represent a significant therapeutic advancement for T2DM patients with cardiovascular risk.
  • Their benefits extend beyond glucose lowering, addressing multiple facets of cardiovascular health.
  • Further research is warranted to fully elucidate their long-term cardiovascular protective effects.

Keywords:
ASCVD risk factorsAtherosclerosisCardiovascular diseaseDiabetesGLP-1 agonistsGlucagon-like peptide-1Heart failureMortality

More Related Videos

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice08:01

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice

Published on: May 16, 2021

6.8K
A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

13.2K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
919
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
8.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
848